journal

Lancet Oncology

journal
https://read.qxmd.com/read/31704137/presenting-symptoms-of-cancer-and-stage-at-diagnosis-evidence-from-a-cross-sectional-population-based-study
#1
Minjoung Monica Koo, Ruth Swann, Sean McPhail, Gary A Abel, Lucy Elliss-Brookes, Greg P Rubin, Georgios Lyratzopoulos
BACKGROUND: Early diagnosis interventions such as symptom awareness campaigns increasingly form part of global cancer control strategies. However, these strategies will have little impact in improving cancer outcomes if the targeted symptoms represent advanced stage of disease. Therefore, we aimed to examine associations between common presenting symptoms of cancer and stage at diagnosis. METHODS: In this cross-sectional study, we analysed population-level data from the English National Cancer Diagnosis Audit 2014 for patients aged 25 years and older with one of 12 types of solid tumours (bladder, breast, colon, endometrial, laryngeal, lung, melanoma, oral or oropharyngeal, ovarian, prostate, rectal, and renal cancer)...
November 5, 2019: Lancet Oncology
https://read.qxmd.com/read/31704136/earlier-diagnosis-the-importance-of-cancer-symptoms
#2
Katriina Whitaker
No abstract text is available yet for this article.
November 5, 2019: Lancet Oncology
https://read.qxmd.com/read/31704135/denosumab-for-giant-cell-tumour-of-bone-success-and-limitations
#3
John H Healey
No abstract text is available yet for this article.
November 5, 2019: Lancet Oncology
https://read.qxmd.com/read/31704134/denosumab-in-patients-with-giant-cell-tumour-of-bone-a-multicentre-open-label-phase-2-study
#4
Sant Chawla, Jean-Yves Blay, Piotr Rutkowski, Axel Le Cesne, Peter Reichardt, Hans Gelderblom, Robert J Grimer, Edwin Choy, Keith Skubitz, Leanne Seeger, Scott M Schuetze, Robert Henshaw, Tian Dai, Danielle Jandial, Emanuela Palmerini
BACKGROUND: Giant-cell tumour of bone (GCTB) is a rare, locally aggressive osteoclastogenic stromal tumour of the bone. This phase 2 study aimed to assess the safety and activity of denosumab in patients with surgically salvageable or unsalvageable GCTB. METHODS: In this multicentre, open-label, phase 2 study done at 30 sites in 12 countries we enrolled adults and skeletally mature adolescents (aged ≥12 years) weighing at least 45 kg with histologically confirmed and radiographically measurable GCTB, Karnofsky performance status 50% or higher (Eastern Cooperative Oncology Group status 0, 1, or 2), and measurable active disease within 1 year of study enrolment...
November 5, 2019: Lancet Oncology
https://read.qxmd.com/read/31679982/early-intervention-effective-in-smouldering-multiple-myeloma
#5
Elizabeth Gourd
No abstract text is available yet for this article.
October 31, 2019: Lancet Oncology
https://read.qxmd.com/read/31679981/leep-for-cervical-neoplasia-recurrence-in-hiv-positive-patients
#6
Manjulika Das
No abstract text is available yet for this article.
October 31, 2019: Lancet Oncology
https://read.qxmd.com/read/31669156/lorlatinib-a-new-treatment-option-for-ros1-positive-lung-cancer
#7
Michaël Duruisseaux
No abstract text is available yet for this article.
October 25, 2019: Lancet Oncology
https://read.qxmd.com/read/31669155/lorlatinib-in-advanced-ros1-positive-non-small-cell-lung-cancer-a-multicentre-open-label-single-arm-phase-1-2-trial
#8
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy, Holger Thurm, Jean-Francois Martini, Gerson Peltz, Antonello Abbattista, Sherry Li, Sai-Hong Ignatius Ou
BACKGROUND: Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most known resistance mutations in ALK and ROS1. We investigated the antitumour activity and safety of lorlatinib in advanced, ROS1-positive non-small-cell lung cancer (NSCLC). METHODS: In this open-label, single-arm, phase 1-2 trial, we enrolled patients (aged ≥18 years) with histologically or cytologically confirmed advanced ROS1-positive NSCLC, with or without CNS metastases, with an Eastern Cooperative Oncology Group performance status of 2 or less (≤1 for phase 1 only) from 28 hospitals in 12 countries worldwide...
October 25, 2019: Lancet Oncology
https://read.qxmd.com/read/31668850/palbociclib-plus-exemestane-with-gonadotropin-releasing-hormone-agonist-versus-capecitabine-in-premenopausal-women-with-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-kcsg-br15-10-a-multicentre-open-label-randomised-phase-2-trial
#9
Yeon Hee Park, Tae-Yong Kim, Gun Min Kim, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, Hee-Jun Kim, Han Jo Kim, Jong In Lee, Su-Jin Koh, Ji-Yeon Kim, Kyung-Hun Lee, Joohyuk Sohn, Sung-Bae Kim, Jin-Seok Ahn, Young-Hyuck Im, Kyung Hae Jung, Seock-Ah Im
BACKGROUND: Endocrine treatment is recommended by clinical guidelines as the preferred treatment option for premenopausal as well as postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. In real-world clinical practice, however, a substantial number of patients are treated with chemotherapy. We aimed to compare the clinical antitumour activity and safety of palbociclib plus endocrine therapy with that of capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer...
October 24, 2019: Lancet Oncology
https://read.qxmd.com/read/31668849/alleviation-of-radiotherapy-induced-oral-mucositis
#10
Elizabeth Gourd
No abstract text is available yet for this article.
October 24, 2019: Lancet Oncology
https://read.qxmd.com/read/31668848/promising-radiotherapy-classifier-for-early-breast-cancer
#11
Manjulika Das
No abstract text is available yet for this article.
October 24, 2019: Lancet Oncology
https://read.qxmd.com/read/31668847/endocrine-based-therapy-versus-chemotherapy-in-advanced-breast-cancer
#12
Marie Robert, Nicholas Turner
No abstract text is available yet for this article.
October 24, 2019: Lancet Oncology
https://read.qxmd.com/read/31668593/reducing-infection-related-morbidity-and-mortality-in-patients-with-myeloma
#13
Karthik Ramasamy
No abstract text is available yet for this article.
October 23, 2019: Lancet Oncology
https://read.qxmd.com/read/31668592/levofloxacin-prophylaxis-in-patients-with-newly-diagnosed-myeloma-teamm-a-multicentre-double-blind-placebo-controlled-randomised-phase-3-trial
#14
Mark T Drayson, Stella Bowcock, Tim Planche, Gulnaz Iqbal, Guy Pratt, Kwee Yong, Jill Wood, Kerry Raynes, Helen Higgins, Bryony Dawkins, David Meads, Claire T Hulme, Irene Monahan, Kamaraj Karunanithi, Helen Dignum, Edward Belsham, Jeff Neilson, Beth Harrison, Anand Lokare, Gavin Campbell, Michael Hamblin, Peter Hawkey, Anna C Whittaker, Eric Low, Janet A Dunn
BACKGROUND: Myeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of patients will have a serious infection within 3 months of diagnosis. We aimed to assess whether patients newly diagnosed with myeloma benefit from antibiotic prophylaxis to prevent infection, and to investigate the effect on antibiotic-resistant organism carriage and health care-associated infections in patients with newly diagnosed myeloma...
October 23, 2019: Lancet Oncology
https://read.qxmd.com/read/31629657/post-operative-salvage-androgen-deprivation-and-radiotherapy-for-prostate-cancer
#15
Anthony V D'Amico
No abstract text is available yet for this article.
October 16, 2019: Lancet Oncology
https://read.qxmd.com/read/31629656/short-term-androgen-deprivation-therapy-combined-with-radiotherapy-as-salvage-treatment-after-radical-prostatectomy-for-prostate-cancer-getug-afu-16-a-112-month-follow-up-of-a-phase-3-randomised-trial
#16
Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, Jean-Léon Lagrange, Stéphane Supiot, Yazid Belkacemi, Didier Peiffert, Nedla Allouache, Bernard M Dubray, Stéphanie Servagi-Vernat, Jean-Philippe Suchaud, Gilles Crehange, Stéphane Guerif, Meryem Brihoum, Nicolas Barbier, Pierre Graff-Cailleaud, Alain Ruffion, Sophie Dussart, Céline Ferlay, Sylvie Chabaud
BACKGROUND: Radiotherapy is the standard salvage treatment after radical prostatectomy. To date, the role of androgen deprivation therapy has not been formally shown. In this follow-up study, we aimed to update the results of the GETUG-AFU 16 trial, which assessed the efficacy of radiotherapy plus androgen suppression versus radiotherapy alone. METHODS: GETUG-AFU 16 was an open-label, multicentre, phase 3, randomised, controlled trial that enrolled men (aged ≥18 years) with Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed adenocarcinoma of the prostate (but no previous androgen suppression or pelvic radiotherapy), stage pT2, T3, or T4a (bladder neck involvement only) and pN0 or pNx according to the tumour, node, metastasis (TNM) staging system, whose prostate-specific antigen (PSA) concentration increased from 0·1 ng/mL to between 0·2 ng/mL and 2·0 ng/mL after radical prostatectomy, without evidence of clinical disease...
October 16, 2019: Lancet Oncology
https://read.qxmd.com/read/31628017/tumour-treating-fields-for-mesothelioma-controversy-versus-opportunity
#17
Dean A Fennell
No abstract text is available yet for this article.
October 15, 2019: Lancet Oncology
https://read.qxmd.com/read/31628016/tumour-treating-fields-in-combination-with-pemetrexed-and-cisplatin-or-carboplatin-as-first-line-treatment-for-unresectable-malignant-pleural-mesothelioma-stellar-a-multicentre-single-arm-phase-2-trial
#18
Giovanni L Ceresoli, Joachim G Aerts, Rafal Dziadziuszko, Rodryg Ramlau, Susana Cedres, Jan P van Meerbeeck, Manlio Mencoboni, David Planchard, Antonio Chella, Lucio Crinò, Maciej Krzakowski, Jörn Rüssel, Antonio Maconi, Letizia Gianoncelli, Federica Grosso
BACKGROUND: Tumour Treating Fields (TTFields) are a regional, antimitotic treatment for solid tumours, which is based on the delivery of low-intensity alternating electric fields. The aim of the STELLAR study was to test the activity of TTFields delivered to the thorax in combination with systemic chemotherapy for the front-line treatment of patients with unresectable malignant pleural mesothelioma. METHODS: STELLAR was a prospective, single-arm, phase 2 trial done at 12 European academic and non-academic sites (five in Italy, three in Poland, one in France, one in Belgium, one in Spain, and one in the Netherlands) for treatment-naive patients with histologically confirmed unresectable malignant pleural mesothelioma...
October 15, 2019: Lancet Oncology
https://read.qxmd.com/read/31607543/targeted-therapy-for-braf-mutant-colorectal-cancer
#19
Ashray Gunjur
No abstract text is available yet for this article.
October 10, 2019: Lancet Oncology
https://read.qxmd.com/read/31606419/patient-reported-quality-of-life-after-tisagenlecleucel-infusion-in-children-and-young-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukaemia-a-global-single-arm-phase-2-trial
#20
Theodore W Laetsch, Gary Douglas Myers, André Baruchel, Andrew C Dietz, Michael A Pulsipher, Henrique Bittencourt, Jochen Buechner, Barbara De Moerloose, Kara L Davis, Eneida Nemecek, Timothy Driscoll, Francoise Mechinaud, Nicolas Boissel, Susana Rives, Peter Bader, Christina Peters, Himalee S Sabnis, Stephan A Grupp, Gregory A Yanik, Hidefumi Hiramatsu, Heather E Stefanski, Lawrence Rasouliyan, Lan Yi, Sweta Shah, Jie Zhang, Andrew C Harris
BACKGROUND: The ELIANA trial showed that 61 (81%) of 75 paediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia achieved overall remission after treatment with tisagenlecleucel, a chimeric antigen receptor targeted against the CD19 antigen. We aimed to evaluate patient-reported quality of life in these patients before and after tisagenlecleucel infusion. METHODS: ELIANA, a global, single-arm, open-label, phase 2 trial, was done in 25 hospitals across Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Norway, Spain, and the USA...
October 9, 2019: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"